AISLING CAPITAL
Aisling Capital believes the next decade will be marked by a revolution in healthcare driven by new therapeutics generated by biotechnology. The completion of the human genome has given scientists new insights into the causes of human disease. These insights, combined with the past 20 years of developments in the biotechnology industry, are leading to rapid expansion of novel approaches toward the diagnosis, prevention, and treatment of life-threatening illnesses. These advances have led to an ever-increasing demand for capital to complete the development and commercialization of new therapeutics. Our goal is to support the leading global healthcare companies that are building on these technical and medical breakthroughs to commercialize new healthcare products.
AISLING CAPITAL
Industry:
Biotechnology Health Care Venture Capital
Founded:
2000-01-01
Status:
Active
Contact:
(212) 651-6379
Email Addresses:
[email protected]
Technology used in webpage:
IPhone / Mobile Compatible Viewport Meta SPF WordPress Google Maps Amazon SSL By Default IPv6 ReCAPTCHA Nginx
Similar Organizations
Arctic Therapeutics
Arctic Therapeutics (AT) uses bioinformatic approaches and AI to eliminate major risks associated with traditional drug development.
PolyCore Therapeutics
PolyCore Therapeutics’ team of life sciences scientists is dedicated to developing breakthrough treatments for CNS Diseases.
RegDesk
Bringing Speed and Certainty to Life Sciences
Rx Green Technologies
Rx Green Technologies delivers and supports research-backed products to commercial cannabis cultivators.
Stabiliz Orthopaedics
Stabiliz Orthopaedics develops novel enhancements for orthopedic medical devices using FDA-approved technologies.
Tivorsan Pharmaceuticals
Tivorsan Pharmaceuticals is a protein therapeutics company that focuses on treating neuromuscular disorders.
Tmunity Therapeutics
Tmunity Therapeutics is developing novel products to unleash the immunological potential of T cells
Tridiuum
Tridiuum is a digital health company that is advancing the treatment of behavioral health conditions.
Current Employees Featured
Founder
Investments List
| Date | Company | Article | Money raised |
|---|---|---|---|
| 2024-05-02 | BridgeBio Oncology Therapeutics | Aisling Capital investment in Venture Round - BridgeBio Oncology Therapeutics | 200 M USD |
| 2024-01-22 | CalciMedica | Aisling Capital investment in Post-IPO Equity - CalciMedica | 55 M USD |
| 2023-12-12 | Bicara Therapeutics | Aisling Capital investment in Series C - Bicara Therapeutics | 165 M USD |
| 2023-08-16 | COMPASS Pathways | Aisling Capital investment in Post-IPO Equity - COMPASS Pathways | 125 M USD |
| 2023-02-07 | Garuda Therapeutics | Aisling Capital investment in Series B - Garuda Therapeutics | 62 M USD |
| 2022-09-12 | Forge Biologics | Aisling Capital investment in Series C - Forge Biologics | 90 M USD |
| 2022-06-14 | Dren Bio | Aisling Capital investment in Series B - Dren Bio | 65 M USD |
| 2021-11-03 | Antios Therapeutics | Aisling Capital investment in Series B - Antios Therapeutics | 75 M USD |
| 2021-09-23 | Garuda Therapeutics | Aisling Capital investment in Series A - Garuda Therapeutics | 72 M USD |
| 2021-07-15 | Wugen | Aisling Capital investment in Series B - Wugen | 172 M USD |
More informations about "Aisling Capital"
About - Aisling Capital
Aisling Capital makes investment decisions driven by fundamental assessment of scientific, regulatory, financial and commercial risks. Given our investment team’s broad skillset, we …See details»
Aisling Capital - Crunchbase Investor Profile
Aisling Capital believes the next decade will be marked by a revolution in healthcare driven by new therapeutics generated by biotechnology. The completion of the human genome has given scientists new insights into the …See details»
Portfolio - Aisling Capital
Aisling Capital invests in products, technologies and businesses that advance health. In addition to investing in companies developing pharmaceutical, biotechnology and medical products, …See details»
Aisling Capital – Divestopedia
Nov 9, 2023 Aisling Capital is a leading investment firm that advises investment funds that invest in products, technologies, and global businesses that advance health. Aisling Capital is led by …See details»
Aisling Capital - Investments, Portfolio & Company Exits
Aisling Capital 's most notable exits include Poseida Therapeutics, COMPASS Pathways, and Biomea Fusion. Which industries has this organization had the most exits in? Show . Poseida …See details»
Aisling Capital Overview | SignalHire Company Profile
Aisling Capital is a investment company company that has been in the industry for 23 years. The company currently specializes in the Venture Capital & Private Equity area. ... Organization …See details»
Aisling Capital - LinkedIn
Aisling Capital believes the next decade will be marked by a revolution in healthcare driven by new therapeutics generated by biotechnology. The completion of the human genome has …See details»
Aisling Capital - Private Equity List
AISLING CAPITAL IS A LEADING INVESTMENT FIRM THAT INVESTS IN COMPANIES DEVELOPING AND COMMERCIALIZING IMPORTANT AND INNOVATIVE HEALTHCARE …See details»
Aisling Capital - raizer.app
Aisling Capital believes the next decade will be marked by a revolution in healthcare driven by new therapeutics generated by Learn which startups Aisling Capital invests in, number of …See details»
Aisling Capital Portfolio Companies - lb.crunchbase.com
Organizations invested in by Aisling Capital. Start Free Trial . Chrome ExtensionSee details»
Aisling Capital investment portfolio - PitchBook
Aisling Capital General Information Company Description. Founded in 2000, Aisling Capital is a venture capital firm based in New York, New York. The firm seeks to invest in healthcare & life …See details»
Aisling Capital - Funding, Financials, Valuation & Investors
Aisling Capital has raised a total of $1.1B across 3 funds, their latest being Aisling Capital New Fund. This fund was announced on Nov 2, 2017 and raised a total of . obfuscated. obfuscated. …See details»
Aisling Capital IV: Fund Performance - PitchBook
Aug 19, 2015 Aisling Capital IV will focus on the life sciences sector, targeting late-stage investments that help companies developing novel medical therapies to complete clinical …See details»
Team - Aisling Capital
Dr. Aguiar joined Aisling in 2016 and serves as a Partner. Prior to Aisling, Dr. Aguiar was a partner at Thomas, McNerney and Partners, a $600 million healthcare-focused venture capital …See details»
Aisling Capital V: Fund Performance - PitchBook
May 26, 2021 Aisling Capital V is a 2019 vintage later stage venture capital fund managed by Aisling Capital. The fund is based in New York, New York and invests in the United States. …See details»
Aisling Capital - Updates, News, Events, Signals & Triggers
Aisling Capital believes the next decade will be marked by a revolution in healthcare driven by new therapeutics generated by. Search Crunchbase. Start Free Trial . Chrome Extension. …See details»
AISLING CAPITAL MANAGEMENT LP - WhaleWisdom.com
Aisling Capital Management is based out of New York. Aisling Capital Management is a hedge fund with 3 clients and discretionary assets under management (AUM) of $515,733,599 (Form …See details»
Aisling Capital - Contacts, Employees, Board Members
Aisling Capital has 9 current employee profiles, including Managing Partner Steven A. Elms. Contacts. Edit Contacts Section. Job Department. Protected Content. Founder and Senior …See details»
News - Aisling Capital
Wayne, PA — November 18, 2024 — Aclaris Therapeutics, Inc. (NASDAQ: ACRS) (the “Company” or “Aclaris”), a clinical-stage biopharmaceutical company focused on developing …See details»